1. Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. (1st December 2020) Authors: Leeuwenkamp, O.; Smith-Palmer, J.; Ortiz, R.; Werner, A.; Valentine, W.; Blachier, M.; Walter, T. Journal: Journal of medical economics Issue: Volume 23:Number 12(2021) Page Start: 1534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗